Clinical data
ATC code None
Legal status
Legal status
  • Investigational
PubChem (CID) 11539381
ChemSpider 9714160
Chemical and physical data
Formula C20H18F3N3O3S
Molar mass 437.435
3D model (Jmol) Interactive image

MBX-8025 is a PPARδ receptor agonist that is being investigated for drug use by Metabolex.[2][3] According to a press release they are examining its potential use for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). The compound, formerly known as RWJ-800025, was licensed from Janssen Pharmaceutica NV.[4]

See also


  1. Zhu, F.; Han, L.; Zheng, C.; Xie, B.; Tammi, M. T.; Yang, S.; Wei, Y.; Chen, Y. (2009). "What Are Next Generation Innovative Therapeutic Targets? Clues from Genetic, Structural, Physicochemical, and Systems Profiles of Successful Targets". Journal of Pharmacology and Experimental Therapeutics. 330 (1): 304–315. doi:10.1124/jpet.108.149955. PMID 19357322.
  2. Billin, A. N. (2008). "PPAR-β/δ agonists for Type 2 diabetes and dyslipidemia: An adopted orphan still looking for a home". Expert Opinion on Investigational Drugs. 17 (10): 1465–1471. doi:10.1517/13543784.17.10.1465. PMID 18808307.
  3. Bays, H. E.; Schwartz, S.; Littlejohn, T.; Kerzner, B.; Krauss, R. M.; Karpf, D. B.; Choi, Y. -J.; Wang, X.; Naim, S.; Roberts, B. K. (2011). "MBX-8025, A Novel Peroxisome Proliferator Receptor- Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin". Journal of Clinical Endocrinology & Metabolism. 96 (9): 2889. doi:10.1210/jc.2011-1061.
  4. "Targeting Mixed Dyslipidemia and Metabolic Syndrome".
This article is issued from Wikipedia - version of the 11/9/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.